Kim HA, et al. - In breast cancer patients of the ASTRRA trial with chemotherapy-induced amenorrhea, researchers assessed how accurate post-chemotherapy biological markers are for forecasting ovarian function recovery. Utilizing information of 82 study participants from a single institution in the ASTRRA trial, post-chemotherapy serum levels of anti-müllerian hormone (AMH), estradiol, inhibin B, and other clinical factors associated with chemotherapy-induced amenorrhea were assessed. In predicting the resumption of menstruation, they found that the diagnostic accuracy of age was 38.3%, for estradiol it was 23.3%, and AMH 86.7%. The study findings suggested that post-chemotherapy AMH level could be a relatively accurate predictor of the recovery of ovarian function, determined by the resumption of menstruation in breast cancer subjects with chemotherapy-induced amenorrhea.